Tourmaline Bio Set to Present Key Research at Cardiometabolic Congress
Tourmaline Bio's Participation in Cardiometabolic Health Congress
NEW YORK, Oct. 11, 2024 -- Tourmaline Bio, Inc. (NASDAQ: TRML), a leading clinical biotechnology firm focused on developing innovative treatments for patients suffering from severe immune and inflammatory conditions, has announced that it will feature two significant poster presentations at the forthcoming 19th Annual Cardiometabolic Health Congress (CMHC). This event is scheduled to take place from October 17 to 19, showcasing cutting-edge research in cardiovascular health.
Showcasing Critical Research
The posters presented by Tourmaline Bio will underline the company's ongoing dedication to enhancing the understanding of inflammatory cardiovascular risk and explore potential therapeutic mechanisms associated with IL-6 inhibition. This focus aligns with Tourmaline's mission of improving patient outcomes through transformative therapies.
Announcing the Posters
One of the featured posters will delve into the utilization of high-sensitivity C-reactive protein testing for both primary and secondary atherosclerotic cardiovascular disease (ASCVD) prevention.
Title: Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention
Authors: Emil deGoma, MD; Yung Chyung, MD; John Walsh, MD; C. William Pike, MD; Jananee Muralidharan, MD; Vincent Marino; J. Craig Davis; Saurabh Gombar, MD, PhD; Michael D. Shapiro, DO, MCR.
Exploring IL-6 Inhibition Effects
The second poster will provide insights into the effects of IL-6 inhibition on lipoprotein(a) levels, drawing from a systematic review and meta-analysis, showcasing the ongoing research into cardiovascular health.
Title: Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis
Authors: Saeid Mirzai, DO; Emil deGoma, MD; John Walsh, MD; Raya Mahbuba, MSc; Yung Chyung, MD; Michael D. Shapiro, DO, MCR.
About Tourmaline Bio
Tourmaline Bio is committed to developing groundbreaking therapies aimed at improving the lives of patients faced with transformative immune and inflammatory diseases. The company’s lead product, pacibekitug (also known as TOUR006), showcases significant potential in treatment innovation.
Understanding Pacibekitug
Pacibekitug is an innovative, long-acting, fully-human anti-IL-6 monoclonal antibody that exhibits unique properties such as a remarkably long half-life, low immunogenicity, and high binding affinity to IL-6. The efficacy and safety of pacibekitug have been evaluated in about 450 participants through six completed clinical trials, focusing primarily on autoimmune conditions. Tourmaline is advancing the development of pacibekitug for applications such as thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), among other potential indications in the pipeline.
Company Contacts for More Information
For additional inquiries about Tourmaline Bio and the upcoming presentations at the CMHC, Media Contact: Sarah Mishek from Scient PR can be reached via email at SMishek@ScientPR.com.
For investor-related questions, Lee M. Stern from Meru Advisors is the contact person, available at lstern@meruadvisors.com.
Frequently Asked Questions
What are the main focus areas for Tourmaline Bio at the congress?
Tourmaline Bio will showcase its ongoing research on inflammatory cardiovascular risk and therapeutic mechanisms surrounding IL-6 inhibition.
What is pacibekitug?
Pacibekitug is a long-acting, fully-human anti-IL-6 monoclonal antibody with the potential for treating immune and inflammatory diseases.
How many participants have been involved in clinical trials of pacibekitug?
Pacibekitug has been studied in approximately 450 participants across six completed clinical trials.
What conditions is Tourmaline targeting with pacibekitug?
The initial focus for pacibekitug includes thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
Where can I find more information about Tourmaline Bio's research?
More information can be obtained by reaching out to the media contact or by visiting the official website of Tourmaline Bio.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Flashpoint Announces Sponsorship of OSINT Conference at Citadel
- Global Diagnostic Testing Market Expected to Reach $272.98 Billion
- Blain’s Farm & Fleet Opens Toyland 2024 for Holiday Fun
- Strategic Move: Thames Ventures VCTs to Merge for Growth
- Seattle Hotel Workers Demand Transparency in Resort Fees
- Exploring the Strategic Advantages of Thames Ventures Merger
- TriCelX, Inc. Launches Innovative Flagship Clinic for All
- Stonehage Fleming Wins Impact Award for Digital Innovation Success
- Revolutionizing Advertising: LoopMe Unveils AI Tool for Brands
- Understanding FirstEnergy's Current P/E Ratio Dynamics
Recent Articles
- Alterity Therapeutics Shares Promising Results on ATH434 Data
- Gannett's Exchange Offer and Consent Solicitation Results Unveiled
- Gibraltar Industries Adjusts 2024 Financial Projections
- Vecima Networks Bolsters Services with Falcon V Acquisition
- Exploring Dynacor's Ambitious Gold Processing Project in Africa
- Tourmaline Bio to Present Innovative Research on Cardiometabolic Health
- Polestar Reports Impressive Q3 Car Deliveries and Future Goals
- Better Choice Company to Enter Veterinary Sector with SRx Health
- Global Markets: Crude Oil Dips, Gold Surges Past $2,650
- Understanding the Surge in Uber and Lyft Shares This Week
- BlackRock Reports Impressive Q3 Performance as AUM Surges
- Global Leaders Set to Gather at CONNECTED 2024 Conference
- Turning Point for Super Micro Computer: Opportunities Ahead
- Exploring Nvidia's Bold Move With Upcoming Blackwell GPUs
- AGBA Group and Triller Corp. Set for Merging Milestone
- Balchem Corporation to Host Third Quarter Financial Call
- ATHA Energy Finalizes Agreements to Expand Uranium Exploration
- JANSON Expands Horizons with New International Contract
- Community Associations Institute Challenges Corporate Transparency Act
- Mill Creek Residential Recognized Among Top Real Estate Firms
- Strategic Board Addition at G Mining Ventures Corp.
- Defense Metals Secures $4 Million for Wicheeda Project Enhancements
- NG Energy Successfully Activates Central Processing Facility Production
- Meta's Efforts to Combat Fake Accounts in Moldova's Election
- Genfit's Regulatory Wins: A Boost for Growth and Revenue
- Akebia Therapeutics Sees Buy Rating Boost from CMS Decision
- Crane NXT Maintains Strong Position as Growth Continues
- HUYA Inc. Maintains Momentum Amid Changing Market Dynamics
- Axos Financial: Strong Buy Rating and Promising Market Outlook
- Alpha Tau Medical Continues to Impress Investors with Progress
- Mizuho Securities Projects Growth for Home Depot Amid Rate Cuts
- Genius Sports: Continues to Shine in the Gambling Market
- AMD's Advancing AI Event Elevates Growth Potential and Outlook
- Citi's Concerns Over France's Budget Forecast for 2025
- Fortum Faces Escalating Cyber Threats Amid Regional Tensions
- Indonesia's Bold Move Against Temu: Protecting Local Businesses
- Fastenal's Q3 Performance Exceeds Expectations, Shares Rise
- Wells Fargo Reports Strong Q3 Results, Boosting Shares Significantly
- Navigating the Q3 Earnings Predictions for Market Growth
- Nvidia's Aspirations: Pioneering AI Factories for the Future
- Uncovering Top Dividend Stocks: Investment Opportunities Ahead
- Legal Challenges Unfold Over Corporate Transparency Act Impact
- JPMorgan Chase Faces Profit Decline Amid Loan Provisions
- NMD Pharma Showcases Innovations in Neuromuscular Disease Therapies
- Daily Fund Prices and NAV Updates for WisdomTree ETFs
- Market Trends Amid Earnings Season and Inflation Insights
- Oxford Metrics Enhances Smart Manufacturing with Sempre Group
- AGBA and Triller Set to Finalize Their Exciting Merger Soon
- Jo-Jo Capital Canada Ltd. Sets New Course After Transaction Halt
- U.S. Energy Corp. Achieves Compliance with Nasdaq Standards